title: Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.
abstract: Positron emission tomography (PET) and 11C-raclopride were used to measure the occupancy of central dopamine D2 receptors by a new neuroleptic, CP-88,059-1. In a double blind dose escalation study, seven healthy male subjects received a predose of between 2 mg and 60 mg CP-88,059-1, 5 h before PET scanning. One additional subject was assigned to placebo predose. Receptor occupancy was defined as the percentage reduction in binding potential compared with that seen in the subject predosed with placebo and with that seen in seven unmedicated normal volunteers previously studied. Binding of 11C-raclopride decreased in a dose dependent manner, and 85% dopamine D2 receptor occupancy was achieved with the highest dose of CP-88,059-1. The findings confirm that brain dopamine D2 receptors are blocked by CP-88,059-1 and suggest that an effective antipsychotic dose will be between 20 mg and 40 mg. The study high-lights the potential of positron emission tomography in the preclinical evaluation of new drugs.
authors.affiliation: MRC Cyclotron Unit, Hammersmith Hospital, London, UK.
authors.forename: C J
authors.initials: CJ
authors.lastname: Bench
authors.forename: A A
authors.initials: AA
authors.lastname: Lammertsma
authors.forename: R J
authors.initials: RJ
authors.lastname: Dolan
authors.forename: P M
authors.initials: PM
authors.lastname: Grasby
authors.forename: S J
authors.initials: SJ
authors.lastname: Warrington
authors.forename: K
authors.initials: K
authors.lastname: Gunn
authors.forename: M
authors.initials: M
authors.lastname: Cuddigan
authors.forename: D J
authors.initials: DJ
authors.lastname: Turton
authors.forename: S
authors.initials: S
authors.lastname: Osman
authors.forename: R S
authors.initials: RS
authors.lastname: Frackowiak
mesh_terms: D000328:Adult; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D018492:Dopamine Antagonists / Q000493:pharmacokinetics* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D010879:Piperazines / Q000493:pharmacokinetics*; D011388:Prolactin / Q000097:blood; D020891:Raclopride; D017448:Receptors, Dopamine D2 / Q000187:drug effects*; D012457:Salicylamides / Q000493:pharmacokinetics*; D013141:Spiro Compounds / Q000493:pharmacokinetics*; D013844:Thiazoles; D014055:Tomography, Emission-Computed
chemical_list: D018492:Dopamine Antagonists; D010879:Piperazines; D017448:Receptors, Dopamine D2; D012457:Salicylamides; D013141:Spiro Compounds; D013844:Thiazoles; D020891:Raclopride; C092292:ziprasidone; D011388:Prolactin